Unfortunately without an upfront payment for the Prostagen test or HIV, more dilutive financing is on the way. How soon? I’m not sure but an SP in the .50 area may not hold up without good PRs, and we know that only significant PRs will move the ticker. Long term, whether CYDY inks a licensing deal or goes it alone, the market value will be significantly higher and thus the stock price, but it will be hard to suffer through as a long term investor. NP has built a great team and adding Prostagene was monumental, But financing has always been an issue and holds many small biotechs back.